Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference
Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference
The Capsida corporate presentation can be accessed by visiting the News section of the Company's website at .THOUSAND OAKS, Calif., Nov. 25, 2024 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida"), a leading fully integrated next-generation gene therapy company developing treatments for rare and common diseases across all ages, today announced that the company will present at the 7th Annual Evercore HealthCONx Conference being held December 3-5, 2024 in Coral Gables, FL.
加利福尼亞州索斯山，2024年11月25日/PRNewswire/ - 首選基因治療公司Capsida Biotherapeutics（"Capsida"）今日宣佈，公司將參加於2024年12月3日至5日在弗羅裏達州科勒爾蓋布爾舉行的第7屆Evercore HealthCONx會議。
Management will highlight progress with Capsida's wholly owned IV-administered gene therapies utilizing the company's proprietary engineered capsids, which enable high transduction levels of neurons, while limiting tropism to non-target organs, such as the liver. The lead programs are for STXBP1 developmental and epileptic encephalopathy (CAP-002) and Parkinson's disease associated with GBA mutations (CAP-003), which are both on track for IND filings in the first half of 2025. A third wholly owned program for Friedreich's ataxia (CAP-004) is in IND-enabling studies.
管理團隊將重點介紹Capsida完全擁有的通過靜脈給藥的基因療法，利用公司專有的工程合成蛋白囊殼，實現神經元的高轉導水平，同時限制對非靶器官，如肝臟的病毒性選擇。主要項目是STXBP1發育性癲癇性腦病（CAP-002）和與GBA突變相關的帕金森病（CAP-003），兩者都計劃在2025年上半年提交IND申請。第三個完全擁有的項目是弗裏德雷希共濟失調（CAP-004），正在進行IND啓動研究。
Capsida's Chief Executive Officer Peter Anastasiou will participate in a fireside chat on Wednesday, December 4, 2024 at 12:55 PM ET. Management will also participate in one-on-one investor meetings.
Capsida首席執行官Peter Anastasiou將在2024年12月4日星期三下午12:55與進行討論。管理團隊還將參加一對一的投資者會議。
The Capsida corporate presentation can be accessed by visiting the News section of the Company's website at .
Capsida公司的企業介紹可以通過訪問公司網站的資訊欄目來查看。
About Capsida Biotherapeutics
Capsida Biotherapeutics is a fully integrated gene therapy company with a central nervous system (CNS) pipeline consisting of disease modifying and potentially curative treatments for rare and more common diseases across all ages. Capsida's wholly owned pipeline includes a potential first-in-class treatment for STXBP1 developmental and epileptic encephalopathy, best-in-class treatment for Parkinson's disease associated with GBA mutations, and best-in-class therapy for Friedreich's ataxia. In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners and originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at Caltech. Visit us at .
關於Capsida生物治療
Capsida Biotherapeutics是一家完全集成的基因治療公司，擁有中樞神經系統（CNS）管道，提供針對罕見和更常見疾病的疾病改善和潛在治癒治療方案。Capsida的完全擁有管道包括STXBP1發育性癲癇性腦病的潛在首創治療，帕金森病相關的GBA突變的最佳治療，以及弗裏德雷希共濟失調的最佳治療。除了自有項目外，公司還與艾伯維公司，Lilly和CRISPR Therapeutics等公司有合作關係。Capsida成立於2019年，由領頭投資者Versant Ventures和Westlake Village BioPartners創建，起源於加州理工學院神經學教授Viviana Gradinaru博士實驗室的突破性研究。訪問我們的網站進行了解。
SOURCE Capsida Biotherapeutics
資訊 來源 Capsida生物治療
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
